Clinical Trial Update: Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of KN026 in combination with KN046 in patients with HER2-positive solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KN026
• KN046

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: HER2-positive Solid Tumors | Phase 2 | Status: COMPLETED